



2013 CTCA Spring Educational Conference - Agenda
Blazing New Trails in TB Control:
Combating Drug Resistance and Applying Molecular Diagnostics
DoubleTree by Hilton San Jose, CA

Thursday, May 30

- 7:30 – 9:00 Registration and Sponsored Breakfast Buffet
- 7:45- 8:30 - Qiagen's TBoss for CI, Presentation and Discussion– (Donner/Siskiyou)
- 9:00- 9:15 Welcome and Announcements, Teeb Al-Samarrai, MD, TB Controller Santa Clara County (Donner/Siskiyou)
- 9:15-10:00 **Jayne Ashe Memorial Keynote: Drug Resistant TB: Is This the New Normal?**
Peter Cegielski, MD, MPH, MDR TB Team Leader, International Research & Programs Branch, Division of TB Elimination (DTE), Centers for Disease Control and Prevention (CDC)
Objectives: At the conclusion of this session participants will be able to:
1. Recognize risk factors for drug resistant TB in their patient population to promote earlier diagnosis of drug resistant TB by learning the epidemiology of drug resistant TB internationally and within the U.S.
 2. Improve evaluation and treatment of contacts to drug resistant TB by learning about outcomes of contact investigations involving drug resistant TB.
 3. Optimize outcomes in their own patient population regarding treatment of drug resistant TB by learning about factors that impact treatment outcomes for drug resistant TB.
 4. Better understand and use bedaquiline as a new therapy for drug resistant TB.
- 10:00-10:45 **Tuberculosis Genotyping: Beyond Outbreak Detection**
Phil Hopewell, MD, Division of Pulmonary Critical Care, University of California San Francisco (UCSF)
Objectives: At the conclusion of this session participants will be able to describe:
1. Variable host-pathogen compatibility
 2. The impact of lineages and sublineages of *M. tuberculosis* as well as drug resistant associated mutations on pathogenicity and the possible consequences in TB control strategies and drug and vaccine design.
- 10:45-11:15 Break
- 11:15-12:00 **California Department of Public Health TB Update**
Pennan Barry, MD, MPH, Chief, Surveillance and Epidemiology Section, TB Control Branch (TBCB), California Department of Public Health (CDPH)
Objectives: At the conclusion of this session participants will be able to:
1. More efficiently focus local TB control program efforts by learning about patient populations most affected by TB in California.
 2. Describe molecular diagnostic tests for diagnosing TB and drug-resistant TB and explain how use of these tests can benefit TB programs.
- 12:00-1:00 Awards Luncheon
Awards in order of presentation: Outgoing Executive Committee Members: Louise McNitt, MD, MPH and Jenny Hernandez, PHN Honorary Members (TBA), Andy Lopez (TBA), Brenda Ashkar (TBA), Private Partner (TBA) and Henry A. Renteln (TBA)

1:00-1:30 Break

1:30-3:00 Breakout Sessions I

Using Quantitative IGRA Results to Inform Clinical Decisions (Siskiyou) DOES NOT REPEAT

Moderated by Barbara Cole, PHN

Wendy Thanassi, MD, VA Occupational Health

Niaz Banaei, MD, Director, Clinical Microbiology, Stanford Hospital and Clinics

Gerald H. Mazurek, MD, MPH, CDC DTBE

Objective: At the conclusion of this session participants will be able to:

Understand the issues related to interpretation of quantitative IGRA values needed to inform clinical decision making for patient care.

Using new therapies and molecular diagnostics in managing MDR TB: a case-based presentation (Donner) REPEATS

Moderator by Louise McNitt, MD, MPH

Peter Cegielski, MD, MPH, DTE, CDC

Claudia Jonah, MD, Health Officer and TB Controller, Kern County Department of Health Services

Ed Desmond, PhD, Chief Microbial and Mycology Section, Microbial Diseases Laboratory, CDPH

Objectives: At the conclusion of this session participants will:

1. Improve the timely diagnosis of drug resistant TB by learning about new molecular diagnostics including pyrosequencing and whole genome sequencing.
2. Improve their medical management of drug resistant TB by learning about therapeutic options for the treatment of drug resistant TB, including bedaquiline.

Utilization of NAATs for TB Control (Carmel and Monterey) REPEATS

Moderators: Charles M. Crane, MD, MPH (1:30-3:30); Amit Chitnis, MD, MPH (3:30-5:00)

Luke Davis, MD, MAS; UCSF

Julie Low, MD; TB Controller, Orange County Health Care Agency Public Health Services

Lisa Pascopella, PhD; TBCB, CDPH

Objective: At the conclusion of this session participants will:

Increase use of NAATs to be able to reduce diagnostic delays and prevent TB transmission

3:00-3:30 Break

3:30-5:00 Breakout II

News from the Frontier: LTBI Treatment with 12 dose INH-RPT (Siskiyou)

Moderator: Jenny Hernandez, PHN

National Perspective: Christine Ho, MD, MPH, Medical Officer, DTE CDC

Local Program: Thomas Bertsch, MD, Sacramento Health and Human Services Public Health

California: Neha Shah, MD, MPH, Lieutenant Commander, U.S. Public Health Service, Field Medical Officer, DTE, CDC

Objective: At the conclusion of this session participants will:

1. Identify the recommendations for use of 3HP Regimen
2. Identify challenges and solutions to implementing 3HP

NAHPF Business Meeting 4:30-5:00 PM

1. State Report – Lisa True
2. Charter Revisions
3. Nomination and Election of Officers
4. Drawing
5. Nurses Open Forum

<https://www.surveymonkey.com/s/CTCA2013>

5:15-6:30 CITC Training: Case Studies / Radiology Review (Donner) ONLY IN SAN JOSE, CA

Conference Sponsors/Exhibitors

Cellestis, A Qiagen Company

Cepheid

Oxford Immunotec, Inc.

Westprime Healthcare

Blazing New Trails in TB Control: Combating Drug Resistance and Applying Molecular Diagnostics

California TB Controllers Association

Thursday May 30, 2013

CONTINUING EDUCATION CREDITS

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Curry International Tuberculosis Center and The California Tuberculosis Controllers Association. The Curry International Tuberculosis Center is accredited by the ACCME to provide continuing medical education for physicians. This conference is approved for 6 continuing education hours.

The Curry International Tuberculosis Center designates this educational activity for a maximum of 6 *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Curry International Tuberculosis Center is approved as a provider of continuing education by the California State Board of Registered Nursing, Provider Number CEP 12308. This conference is approved for up to 6 continuing education contact hours.

Certificates will be mailed approximately 8-10 weeks after the course to all participants who requested credits on their applications and who successfully complete the course. Successful completion includes signing-in each day, attending the entire course and completing and turning in an evaluation form, and participating in one longer-term post-course activity (survey).

Blazing New Trails in TB Control: Combating Drug Resistance and Applying Molecular Diagnostics

California TB Controllers Association

Thursday May 30, 2013

The following Faculty Members and Planning Committee Members disclosed no financial or other conflict of interest in the content gathered and presented for this event.

Faculty Members:

Peter Cegielski, Phil Hopewell, Pennan Barry, Ed Desmond, Claudia Jonah, Luke Davis, Julie Low, Lisa Pascopella, Wendy Thanassi, Niaz Banaei, Gerald Mazurek, Neha Shah, Christine Ho, Thomas Bertsch,

Planning Committee Members:

Julie Higashi, Mike Carson, Charlie Crane, Louise McNitt, Barbara Cole, Cathy Miller, John Jereb